Trials / Completed
CompletedNCT01466660
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 319 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib | afatinib once daily |
| DRUG | gefitinib | Gefitinib once daily |
Timeline
- Start date
- 2011-12-13
- Primary completion
- 2016-04-08
- Completion
- 2019-04-12
- First posted
- 2011-11-08
- Last updated
- 2020-04-07
- Results posted
- 2017-06-19
Locations
63 sites across 14 countries: Australia, Canada, China, France, Germany, Hong Kong, Ireland, Norway, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT01466660. Inclusion in this directory is not an endorsement.